Translational studies in X-linked adrenoleukodystrophy

Engelen, M.

Citation for published version (APA):
Chapter 5

Bezafibrate for X-linked adrenoleukodystrophy

Marc Engelen¹,³, Luc Tran², Rob Ofman², Josephine Brennecke², Ann B. Moser⁴, Inge M.E. Dijkstra³, Ronald J.A. Wanders², Bwee Tien Poll-The¹,³, Stephan Kemp²,³

¹Department of Neurology, ²Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, and ³Department of Pediatric Neurology/Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁴Department of Neurogenetics, Kennedy Krieger Institute, Baltimore, MD, USA.

*PLoS ONE (2012) 7(7): e41013*
Abstract

X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene and is characterized by impaired beta-oxidation of very-long-chain fatty acids (VLCFA) and subsequent VLCFA accumulation in tissues. In adulthood X-ALD most commonly manifests as a gradually progressive myelopathy, (adrenomyeloneuropathy; AMN) without any curative or disease modifying treatments. We recently showed that bezafibrate (BF), a drug used for the treatment of hyperlipidaemia, reduces VLCFA accumulation in X-ALD fibroblasts by inhibiting ELOVL1, an enzyme involved in the VLCFA synthesis. We therefore designed a proof-of-principal clinical trial to determine whether BF reduces VLCFA levels in plasma and lymphocytes of X-ALD patients. Ten males with AMN were treated with BF for 12 weeks at a dose of 400 mg daily, followed by 12 weeks of 800 mg daily. Every 4 weeks patients were evaluated for side effects and blood samples were taken for analysis. Adherence was good as indicated by a clear reduction in triglycerides. There was no reduction in VLCFA in either plasma or lymphocytes. Plasma levels of BF did not exceed 25 µmol/L. We concluded that BF, at least in the dose given, is unable to lower VLCFA levels in plasma or lymphocytes in X-ALD patients. It is unclear whether this is due to the low levels of BF reached in plasma. Our future work is aimed at the identification of highly-specific inhibitors of ELOVL1 that act at much lower concentrations than BF and are well tolerated. BF appears to have no therapeutic utility in X-ALD.
Introduction

X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder characterized by impaired beta-oxidation of very long-chain fatty acids (VLCFA) and accumulation of these VLCFA in tissues (Moser et al 2007). It is caused by mutations in the *ABCD1* gene (www.x-ald.nl) (Moser et al 1993). The disease is highly variable in clinical expression, however, in adulthood it most frequently manifests as a gradually progressive myelopathy and peripheral neuropathy (adrenomyeloneuropathy phenotype or AMN) (Moser et al 2007). Treatment for AMN is purely symptomatic and currently there is no proven intervention that can halt progression of the disease (Moser et al 2007). We identified ELOVL1 as the enzyme responsible for the synthesis of VLCFA (Ofman et al 2010), and demonstrated that siRNA-mediated knockdown of ELOVL1 lowers VLCFA levels in X-ALD fibroblasts (Ofman et al 2010). Next, we showed that bezafibrate (BF) reduces VLCFA levels in X-ALD fibroblasts by directly inhibiting ELOVL1 (Engelen et al 2012). BF is a drug of the fibrate class for the treatment of dyslipidaemia and has a proven safety profile for (long-term) use in humans (Miller and Spence, 1998). We therefore designed a proof of principal clinical trial to test whether BF can reduce VLCFA levels in the plasma and lymphocytes of patients with X-ALD.

![Figure 1: Schematic representation of the BEZA trial design.](image_url)

Methods

The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1 (online only). The BEZA trial study protocol was approved by the Institutional Review Board (Medisch Ethische Toetsings Commissie) of the Academic Medical Center. The trial is registered at clinicaltrials.gov (NCT01165060). Adult men with biochemically and genetically proven X-ALD without contra-indications for the use of BF were eligible for inclusion. All participating patients were evaluated at baseline for eligibility and received trial medication after written informed consent was obtained. They were evaluated at intervals of 4 weeks until the end of the trial at 24 weeks. The initial dose of BF was 400 mg per day, which was subsequently increased to 800 mg per day at week 12 (Figure 1). At each visit side effects were monitored, a general physical examination including weight was performed and blood samples taken. Blood samples were taken in the morning after an overnight fast before the first medication dose. Blood samples were analyzed at the laboratory for clinical chemistry for routine laboratory tests. VLCFA and BF levels were analyzed as previously described (Masnatta et al 1996; Valianpour et al 2003). Lysophosphatidylcholine-C26:0 (C26:0 lysoPC) was analyzed in bloodspots (Hubbard et al 2009). Data were analyzed with PASW statistics, version 18 (IBM). Statistical significance was evaluated with Student’s paired t-test.
Chapter 5

Results

Ten males with AMN participated in the trial. No side effects that necessitated discontinuation of the trial medication occurred. Body weight was unchanged (Table 1). There was a clear reduction in plasma triglycerides (1.34 mmol/L to 0.70 mmol/L at BF 400 mg and 0.71 mmol/L at BF 800 mg), and to a lesser extent a decrease in total cholesterol and LDL-cholesterol. There was also an increase in HDL-cholesterol (Table 1). These are known effects of BF and confirm patient adherence. There was no consistent reduction in C26:0 in plasma or lymphocytes, neither at 400 nor at 800 mg BF per day (Table 1). We observed an increase in plasma C22:0 and C24:0 at a dose of 800 mg BF per day. The amount of C26:0 lysoPC was unchanged in blood spots after 24 weeks of treatment with BF. The plasma level of BF did not exceed 25 µmol/L at the highest dose of 800 mg BF per day.

Table 1: Summary of the different parameters measured at the indicated time point in the trial.

<table>
<thead>
<tr>
<th>Plasma</th>
<th>Baseline</th>
<th>BF 400 mg</th>
<th>BF 800 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>5.57 ± 1.42</td>
<td>4.80 ± 0.88**</td>
<td>4.85 ± 0.84*</td>
</tr>
<tr>
<td>(mmol/L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>3.67 ± 1.17</td>
<td>2.93 ± 0.80**</td>
<td>2.90 ± 0.73*</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.39 ± 0.25</td>
<td>1.57 ± 0.25***</td>
<td>1.64 ± 0.26***</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.34 ± 0.79</td>
<td>0.70 ± 0.31**</td>
<td>0.71 ± 0.22*</td>
</tr>
<tr>
<td>C22:0 (µmol/L)</td>
<td>43.32 ± 9.25</td>
<td>45.37 ± 8.12</td>
<td>55.02 ± 9.74**</td>
</tr>
<tr>
<td>C24:0 (µmol/L)</td>
<td>62.56 ± 11.68</td>
<td>64.08 ± 11.78</td>
<td>82.62 ± 12.50***</td>
</tr>
<tr>
<td>C26:0 (µmol/L)</td>
<td>3.26 ± 0.96</td>
<td>2.56 ± 0.50**</td>
<td>2.99 ± 0.49</td>
</tr>
<tr>
<td>C26:0/C22:0 ratio</td>
<td>0.075 ± 0.015</td>
<td>0.058 ± 0.012</td>
<td>0.056 ± 0.012**</td>
</tr>
<tr>
<td>Bezafibrate (µmol/L)</td>
<td>n.d.</td>
<td>n.d.</td>
<td>10.1 ± 6.7</td>
</tr>
</tbody>
</table>

Lymphocytes

| C22:0 (nmol/mg)      | 5.89 ± 1.03    | 5.85 ± 1.65   | 5.10 ± 1.47   |
| C24:0 (nmol/mg)      | 6.03 ± 0.78    | 6.45 ± 1.85   | 6.42 ± 1.44   |
| C26:0 (nmol/mg)      | 0.35 ± 0.040   | 0.37 ± 0.084  | 0.40 ± 0.11   |
| C26:0/C22:0 ratio    | 0.06 ± 0.01    | 0.06 ± 0.01   | 0.08 ± 0.03   |

bloodspots

| C26:0 lysoPC         | 2.84 ± 1.40    | 2.50 ± 0.89   | 2.63 ± 1.18   |

Weight (kg)

| 86.7 ± 9.3           | n.d.           | 87.9 ± 10.5   |

Summary of the different parameters measured at the indicated time point in the trial. Values are mean ± the standard deviation. Statistically significant differences from the baseline value are indicated. * p < 0.05, ** p < 0.01, *** p < 0.001. n.d. = not determined.
Discussion

The pathophysiology of X-ALD is not well understood, although it seems likely that accumulation of VLCFA is toxic and related to neurodegeneration (Kemp et al 2012). Therefore drugs that reduce the level of VLCFA might be effective in halting or slowing progression of the disease.

Recently, we showed that it is possible to reduce VLCFA in fibroblasts from X-ALD patients by inhibiting the synthesis of VLCFA by the enzyme ELOVL1 (Ofman et al 2010). We later showed that this can also be accomplished by incubating fibroblasts from X-ALD patients with BF (Engelen et al 2012).

BF is a drug that has been in use for decades for the treatment of hypertriglyceridaemia and has an excellent safety profile (Miller and Spence, 1998). Therefore we decided to initiate this small scale proof of principle clinical trial to investigate whether BF reduces VLCFA in plasma and lymphocytes of X-ALD patients. In a previous clinical trial with lovastatin we demonstrated that reduction of plasma VLCFA can be an artifact of LDL reduction and does not reflect a reduction in blood cells (Engelen et al 2010).

Unfortunately, we could not show a reduction of plasma or lymphocyte VLCFA levels. Conversely, there was an unexpected increase in C22:0 and C24:0 levels in plasma. We did not observe this in blood cells or bloodspots.

Our results show that there is no rationale for a large follow-up trial with clinical endpoints utilizing this compound.

The concept of treating X-ALD patients with an inhibitor of VLCFA synthesis remains a feasible option. It seems that BF is simply not efficacious enough. Our previous work suggests that BF is a competitive inhibitor of ELOVL1 (Engelen et al 2012). In our cell culture experiments a high concentration of BF of 400 μmol/L was required to achieve a maximal effect on the level of VLCFA. At this concentration the de novo VLCFA synthesis was reduced to the level in control cells. It is likely that even with the high dose of 800 mg BF per day, the intracellular levels of BF remained inadequate. Indeed, at the highest BF dosage plasma levels did not exceed 25 μmol/L with an average of 10 μmol/L (Table 1). These levels are not peak levels, but rather residual plasma levels. It is unlikely that concentrations even approaching 400 μmol/L were reached. This may explain the lack of in vivo efficacy of BF on our outcome parameters. To achieve the effect of VLCFA reduction, significantly higher BF concentrations are necessary as compared to concentrations indicated for reduction of TG.

Future research will be focused on the identification of specific inhibitors of ELOVL1 that act at much lower concentrations than BF and are well-tolerated. In conclusion, BF appears to have no therapeutic utility in X-ALD.

Acknowledgements

This research was supported by the Netherlands Organization for Scientific Research (VIDI-91786328), the European Union Framework Programme 7 (LeukoTreat 241622) and The Stop ALD Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References


